The FDA panel reviewed multiple clinical trials. One study showed a statistically significant improvement in sexual desire in women treated with the drug compared to placebo. Specifically, the mean change in Female Sexual Function Index (FSFI) scores was 2.8 points higher in the treatment group. Another trial focused on the drug’s impact on subjective sexual experiences, reporting a positive response in a subset of participants experiencing low sexual desire.
Safety data revealed a generally well-tolerated profile. Reported adverse events included headache, nausea, and flushing, occurring with similar frequency in both the treatment and placebo groups. Serious adverse events were rare.
Analysis of specific subgroups highlighted a potential for increased efficacy in women with certain hormonal profiles, though this requires further investigation. Data on long-term safety remain limited, prompting recommendations for continued monitoring.
The panel also considered the limitations of the existing data, including potential biases in study design and the need for larger, more diverse clinical trials to confirm these findings.
Based on the presented data, the panel carefully weighed the potential benefits against the risks. This informs their recommendation regarding approval.
